期刊文献+

取卵后当日添加来曲唑和GnRH-ant预防卵巢过度刺激综合征的疗效观察 被引量:4

Effect of GnRH antagonist and letrozole for prevention of ovarian hyperstimulation syndrome
下载PDF
导出
摘要 目的探讨联合使用来曲唑和促性腺激素释放激素拮抗剂(GnRH-ant)对于防治早发型卵巢过度刺激综合征(OHSS)的效果。方法回顾性分析2018年3月至2019年2月于本院生殖中心接受助孕治疗、因OHSS高风险取消新鲜周期胚胎移植而行全胚冷冻的61例患者的临床资料。根据取卵日是否添加GnRH-ant和来曲唑分为研究组(39例)和对照组(22例)。对照组采用常规防治方法;研究组在常规防治的基础上,加用GnRH-ant和来曲唑。比较两组患者的一般资料、相关实验室指标及OHSS发生情况。结果两组患者的一般资料比较均无显著性差异(P>0.05)。两组患者的扳机日FSH、LH及P水平、≥14 mm卵泡数、获卵数、MⅡ卵数、2PN数、可移植胚胎数、优质胚胎数等比较亦均无显著性差异(P>0.05),研究组扳机日E 2水平显著高于对照组(P<0.05)。两组患者取卵后第3天双侧卵巢平均直径比较无显著性差异(P>0.05),研究组取卵后第3天的E 2水平显著低于对照组(P<0.05),E 2水平下降幅度显著高于对照组(P<0.05)。研究组中度OHSS发生率(7.7%)略低于对照组(13.6%),但无显著性差异(P>0.05)。结论OHSS高危患者在取卵术后当日联合使用来曲唑和GnRH-ant,可明显降低黄体期E 2的水平,且中度OHSS的发生率有降低的趋势。 Objective:To explore the efficiency of using letrozole and GnRH antagonist(GnRH-ant)in prevention of the ovarian hyperstimulation syndrome(OHSS).Methods:The data of 61 OHSS high risk patients who underwent whole embryo freezing treatment due to the high risk of OHSS to cancel fresh-cycle embryo transfer at our reproductive center from March 2018 to February 2019 were retrospectively analyzed.The patients were divided into control group(n=22)and the study group(n=39)according to whether application of letrozole and GnRH-ant on the oocyte retrieval day.The patients in the control group were given conventional preventive treatment.The study group was added GnRH-ant and letrozole other than above preventative treatment.The general data,related laboratory indicators,and the incidence of OHSS were compared between the two groups.Results:There was no significant difference in general information between the two groups of patients(P>0.05).There were also no significant differences in FSH,LH,and progesterone levels on the trigger day,number of follicle≥14 mm,number of oocyte retrieval,MⅡoocyte number,2PN embryos number,transplantable embryos,and high-quality embryos between the two groups(P>0.05).The E 2 level on the trigger day in the study group was significantly higher than that in the control group(P<0.05).There was no significant difference in the mean diameter of bilateral ovaries on the 3 rd day after oocyte retrieval between the two groups(P>0.05).The E 2 level on the 3 rd day after oocyte retrieval in the study group was significantly lower than that in the control group(P<0.05),and the decrease of E 2 level was significantly higher than that of the control group(P<0.05).The incidence of moderate OHSS(7.7%)in the study group was slightly lower than that in the control group(13.6%),but there was no significant difference(P>0.05).Conclusions:Administrating letrozole combined with GnRH-ant on the oocytes retrieval day can reduce E 2 level at luteal phase,and the incidence of moderate OHSS tends to decrease.
作者 周冬梅 宋晖 滑玮 武雁 黄艳红 ZHOU Dong-mei;SONG Hui;HUA Wei;WU Yan;HUANG Yan-hong(Reproductive Medicine Center,Xijing Hospital,the Air Force Medical University,Xi’an 710032)
出处 《生殖医学杂志》 CAS 2020年第2期204-208,共5页 Journal of Reproductive Medicine
基金 西京医院临床新技术新业务(XJGX15Y57)
关键词 来曲唑 促性腺激素释放激素拮抗剂 体外受精-胚胎移植 卵巢过度刺激综合征 Letrozole GnRH antagonist In vitro fertilization-embryo transfer Ovarian hyperstimulation syndrome
  • 相关文献

参考文献7

二级参考文献85

  • 1郑惠丽,倪江.血管内皮生长因子(VEGF)与黄体形成和功能关系的研究概况[J].生殖与避孕,2004,24(4):249-253. 被引量:4
  • 2蔺莉,魏丽惠.米非司酮治疗卵巢过度刺激综合征的实验研究[J].生殖与避孕,2006,26(4):247-249. 被引量:8
  • 3Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syn- drome in women undergoing gonadoWopin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril, 2006, 85 (1):112-20.
  • 4Busso C, M, Garcia-Velasoa JA, etal. The non-ergot derived dopamine agonist quinagolide in pre- vention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-ennm)lled trial. Hum Reprod, 2010, 25(4):995-1004.
  • 5Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril, 2010, 94(2):389-400.
  • 6Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotro- phin-releasing hormone antagonists for assisted reproduc- tive technology. Cochrane Database Syst Rev, 2011(5): CD001750.
  • 7Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperslsulafion syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endoerinol, 2012, 10:32.
  • 8Tsoumpou I, Muglu J, G-elbaya TA, et al. Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final ooeyte maturation in IVF cycles: absence of evidence? Reprod Biomed Online, 2009, 19(1):52-8.
  • 9Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Management of severe early ovarian hyperstimulation syndrome by re- initiation of CmRH antagonist. Reprod Biomed Online, 2007, 15(4):408-12.
  • 10Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online, 2009, 18( 1): 15-20.

共引文献118

同被引文献36

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部